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Impaired endothelial function in patients with nephrotic range protein-
uria. Proteinuria is associated with increased cardiovascular morbidity and
mortality. Release of nitric oxide by the endothelium has been advanced
as an important defense mechanism against vessel-wall damage. In the
present study we therefore tested the hypothesis that proteinuria is
associated with a defect in nitric oxide-dependent vasodilation, by using
venous occlusion plethysmography of the forearm in nine patients with
nephrotic range proteinuria (>3.5 g/24 hr) and normal renal function
(creatinine 83.1 8.7 j.mol/liter), eight patients with active glomerulone-
phritis but normal renal function (creatinine 81.2 5.4 molIliter) and
low range proteinuria (<1.0 g/24 hr), and ten healthy volunteers. We
infused L-NMMA (2 mg/mm) to inhibit basal nitric oxide production,
serotonin (0.1, 0.3 and 1.0 ng/kg/min) as an endothelium-dependent
vasodilator, and nitroprusside (1, 10, 30 and 100 ng/kg/min) as an
endothelium-independent vasodilator into the brachial artery. Adminis-
tration of L-NMMA decreased basal forearm vascular resistance (FVR)
by 30 4% in the nephrotic subjects, 38 4% in the non-nephrotic
patients and by 37 2% in the healthy controls (P = 0.15). Upon the
highest dose of serotonin FVR decreased in nephrotic subjects by 40
5%,which was less than in non-nephrotic patients (56 3%;P < 0.05) or
in healthy controls (55 3%; P < 0.05). The maximal decrease in FVR
upon nitroprusside infusion was not different between the groups (respec-
tively 84 2, 84 3 and 84 2%). The impaired serotonin-induced
vasodilation could be attributed to a defect in nitric oxide production,
since L-NMMA almost completely prevented serotonergic vasodilation.
The defect in agonist-induced nitric oxide release or activity could not be
explained by decreased substrate availability, as infusion of excess L-
arginine (0.2 mg/kg/mm) did not improve vasodilation. The nephrotic
subjects also had an increased lysophosphatidyicholine content in the
low-density-lipoprotein fraction, which has been shown to interfere with
Gi-protein-dependent signal transduction pathways, including serotonin-
induced vasodilation. In conclusion, nephrotic-range proteinuria is accom-
panied by impaired endothelium-dependent vasomotion.
Proteinuria is a prognostic hallmark of renal disease. Its
presence has been found to correlate closely with deterioration of
renal function [1]. In addition, the presence of proteinuria signi-
fies an increased risk for cardiovascular morbidity and mortality.
In patients with nephrotic range proteinuria the risk of cardiovas-
cular infarction is elevated five to six times resulting in an almost
threefold increase in cardiac mortality [2]. Similarly, in patients
with diabetes, hypertension and even in the normal population
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without overt renal disease, proteinuria carries a threefold in-
crease in mortality due to atherosclerotic heart disease [3—5].
Dysfunction and injury of the endothelium is now emerging as
the primary event in the pathogenesis of atherosclerotic vessel
wall damage [6—8]. Nitric oxide release by the endothelium is an
important defense mechanism against atherosclerosis by main-
taining vasodilator tone [9], and by preventing smooth muscle
proliferation [10], thrombosis [11] and transendothelial lipopro-
tein flux [12], which are all key processes in atherosclerosis.
Impaired release of nitric oxide may result in a disturbance of
these anti-atherosclerotic properties of the endothelium, thus
contributing to an atherogenic state [6—8, 13].
In the present study we therefore investigated whether the
presence of nephrotic range proteinuria is associated with a defect
in nitric oxide release or effect. Such a defect may contribute to
the high cardiovascular morbidity in these patients, and this would
offer new therapeutic goals for prevention of cardiovascular
disease.
Methods
Subjects
Endothelial function was measured in three groups, nine pa-
tients with nephrotic range proteinuria (>3.5 g/24 hr; "nephro-
sis"), non-nephrotic patients with active glomerulonephritis, as
indicated by erythrocytes and/or casts in the urinary sediment but
without nephrotic range proteinuria ("glomerulonephritis"), and
ten healthy subjects ("controls"). Clinical characteristics are sum-
marized in Table 1. The histological diagnosis of patients with
nephrotic syndrome was membranous glomerulopathy (N = 5),
minimal lesions (N = 2) and focal segmental glomeruloscierosis(N = 2). Of the non-nephrotic patients with glomerulonephritis
four had IgA nephritis, one focal segmental glomerulosclerosis,
two membranous glomerulopathy and one Alport's disease. None
of the subjects studied had signs of macrovascular atherosclerotic
disease on physical examination and EKG. All patients were
without medication for at least three weeks prior to the investi-
gation. Twelve hours before the study all subjects refrained from
smoking, alcohol and caffeine-containing beverages. The study
protocol was approved by the University Hospital Ethical Com-
mittee for study in humans and every subject gave written
informed consent after extensive explanation of the protocol.
Protocol
Experiments were performed in a quiet room kept at a constant
temperature of 22 to 24°C. During the experiments the subjects
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Table 1. Clinical characteristics
Nephrosis Glomerulonephritis Control
Age years 33.1 4.1 30.1 4.1 27.0 2.2
Sex M/F 7/2 6/2 8/2
Smoking (no smoker/stopped 5/1/3 5/1/2 7/1/2
smoking/smoker)
BMI kg/rn2 24.8 0.7 22.4 0.8 23.6 1.1
Forearm volume ml 1200 100 1185 53 1263 83
Systolic BP mm Hg 124 4 125 4 110 3
Diastolic BP mm Hg
MAP mml-Ig
77
92±2'
78 3°
93±3"
67 2
80±2
Data are means 5EM. Abbreviations are: BMI, body mass index; BP,
blood pressure; MAP, mean arterial pressure.
ap < o.os, "p c 0.01 vs. control
were in the supine position with both forearms stabilized slightly
above the level of the heart. A 22-gauge needle (Arrow, PA, USA)
was inserted into the brachial artery of the non-dominant arm
after local anaesthesia (1% lignocaine). Forearm blood flow
(FBF) in both arms was measured at 10 second intervals by
R-wave triggered venous occlusion plethysmography with mercu-
ry-in-silastic strain-gauges [14]. The upperarm collecting cuffs
were inflated to 40 mm Hg. During forearm blood flow measure-
ment both hands were excluded from the circulation by small wrist
cuffs, which were inflated 40 mm Hg above systolic pressure.
Intra-arterial blood pressure was registered continuously. The
baseline measurements started at least 45 minutes after cannula-
tion of the brachial artery, when FBF had stabilized. Between the
various infusions the wrist cuffs were deflated and sufficient time
(at least 20 mm) was allowed for FBF to return to baseline levels
before the next infusion was started. The following drugs were
infused into the brachial artery: serotonin (5-HT, Sigma Chemical
Co., St. Louis, MO, USA), sodium nitroprusside (SNP, E Merck,
Darmstadt, Germany), L-arginine (L-arginine 10%, Bufa, Uit-
geest, Netherlands) and L-mono-methyl-arginine (L-NMMA,
Sigma Chemical Co.). All drugs were dissolved in 0.9% saline. All
solutions were prepared aseptically from sterile stock solutions or
ampoules on the day of the study and stored at 4°C until use.
The infusion protocol is shown in Figure 1. Serotonin was
administered in a cumulative dose infusion of 0,1, 0.3, and 1.0
ng/kg/min as used by Bruning [15]. Serotonin induced a rapid and
transient vasodilation, followed by persistent vasodilation at low
concentrations. The persistent vasodilation is due to nitric oxide
release [15]. Since steady state persistent vasodilation was reached
after about 3.5 minutes, each serotonin-dose was infused for five
minutes. Nitroprusside was administered in a cumulative dose
infusion of 1, 10, 30 and 100 ng/kg/min [16]. Steady state of FBF
during infusion of nitroprusside was obtained after —1.5 minutes.
Measurements of FBF were therefore performed from 1.5
through three minutes of infusion. These two infusion blocks were
given in random order. Afterwards, the same infusions were given
together with L-arginine, again randomly. L-arginine was co-
infused in a dose of 0.2 mg/kg/mm, equivalent to 15 mg/mm for a
75 kilogram adult. This dosage was chosen, since in a dose of 10
mg/mm L-arginine was capable of reversing part of the L-NMMA
induced vasoconstriction in healthy volunteers [17], and of stim-
ulating acetylcholine-induced vasodilation [18], as well as metha-
choline-induced vasodilation [19] in patients with hypercholester-
olemia. Finally, L-NMMA was infused in a dose chosen near the
top of the dose response-curve reported by Vallence, Collier and
Moncada [17] and Calver, Collier and Vallence [20]. These
studies have shown that during infusion of 1, 2 and 4 .tmol/min
L-NMMA the decrease in forearm blood flow starts to level off
between 2 and 4 jtmol/min. We therefore infused 8 gmol/min (2
mg/mm) to approximate maximal inhibition of nitric oxide syn-
thase. When steady vasoconstriction had been obtained, serotonin
in maximum infusion dose was added to examine nitric oxide-
independent vasodilation by serotonin.
Laboratory parameters
Plasma creatinine, albumin and urinary proteinuria were mea-
sured with standard laboratory methods [21]. Plasma lipoproteins
were separated by density-gradient ultracentrifugation at 4°C for
20 hours in a 50.3 Ti-rotor (Beckman Instruments, Palo Alto, CA,
USA). Phospholipid composition of lipoproteins was analyzed by
thin-layer chromatography as described elsewhere [22]. Phospho-
lipids were visualized with iodine, scraped from the plate, and
phosphorus content of the various species (lysophosphatidylcho-
line (lyso-PC), sphingomyelin, phosphatidylcholine (PC), and
phosphatidylethanolamine) in each lipoprotein was determined
with the modified Bartlett procedure [23]. Cholesterol and phos-
pholipid concentrations were assayed enzymatically, using kits
(respectively Boehringer GmbH, Mannheim, Germany and bio-
Merieux, Marcy-l'Etoile, France). Triglyceride was measured
automatically with a fully automated Hitachi 717 analyzer, using
enzymatic applications with reagents obtained from Boehringer
Mannheim, Germany.
Calculations and statistics
The average value of FBF and intra-arterial pressure was
obtained from the last nine consecutive recordings of each
infusion step, and used for further calculations. Forearm vascular
resistance (FVR) was calculated from the FBF and the concom-
itantly measured mean arterial pressure. Plasma concentrations of
the drugs infused intra-arterially (Cpiasma, in Mmol/liter) were
calculated from the rate of drug infusion (IR, in ng/kg/min), body
wt (W, in kg), hematocrit (Ht), forearm volume (V, in ml), FBF
(in ml/100 ml forearm vol/mm), and molecular weight (MW, in
Daltons) [24]:
IR *W * 100
Cpiasma
=
(1— Ht) *FBF*V* MW
The calculated plasma concentrations and corresponding
changes in FVR from baseline were used to construct individual
Concentration Response Curves by means of a curve fitting
computer program (Graph-Pad, San Diego, CA, USA). In order
to allow statistical analysis of differences between the concentra-
tion response curves, the calculated) plasma concentrations that
induce 50% (EC5O) or 25% (EC25) reduction in FVR, were
estimated from these curves. For nitroprusside, with a mean
maximal effect of 84% reduction of FVR, the ECSO was calcu-
lated. However, the decrease of FVR upon maximal 5-HT stim-
ulation ranged from 26% to 72% and remained below the value of
50% VR reduction in seven out of nine nephrotic patients.
Therefore, the EC25 instead of the EC5O was calculated for 5-HT
induced vasodilation. EC2S and EC5O are expressed as — log
molar.
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Fig. 1. Schematic representation of the inJhsion
protocoL The order of the infusion blocks [A:
serotonin (5-HT) with saline and B:
nitroprusside (SNP) with saline on the one
hand and C: 5-HT with L-arginine and D: SNP
with L-arginine on the other hand] were
randomized (respectively AJB/C/D; B/A/C/D;
A/BID/C; B/AID/C). Each block was followed
by a washout period of at least 20 minutes.
Dosages of 5-HT and SNP are expressed as
ng/kg/min; L-NMMA was administered in a
dose of 2 mg/mm, and L-argmnine in a dose of
0.2 mg/kg/mm.
Results are expressed as mean SEM. Analysis of variance was
used to evaluate the statistical significance between values ob-
tamed in different groups. If variance ratios reached statistical
significance, the difference between the means were analyzed with
the Student-Newman-Keuls test for P < 0.05 and P < 0.01.
Correlations were tested with Spearman-rank order correlation
test.
Results
Baseline
Clinical characteristics of the study groups are shown in Table
1. No statistically significant differences were observed with
respect to age, gender, smoking habit, body mass index and
forearm volume. The duration of disease was 2.1 0.7 years in
the nephrotic group and 6.4 1.4 years in the non-nephrotic
group. Patients with non-nephrotic glomerulonephritis and pa-
tients with nephrotic syndrome had statistically higher systolic
(P < 0.05), diastolic (P < 0.05) and mean arterial pressure (P <
0.01) compared to the control subjects. Modest amounts of leg
edema were present in six patients of the nephrotic group and in
three patients of the glomerulonephritic group.
Table 2 shows the biochemical parameters of the studied
population. Plasma creatinine, hemoglobin and hematocrit were
similar in all groups. The nephrotic subjects obviously had more
proteinuria (6.4 1.2 g/day) than the non-nephrotic patients (0.7
0.2 g/day, P < 0.01), and, consequently, lower plasma albumin.
In the nephrotic group significantly higher values for triglycerides,
total cholesterol, LDL-cholesterol and total phospholipids were
observed. Lyso-PC as a fraction of total phospholipids was not
significantly different. In contrast, lyso-PC content in the low
density lipoprotein (LDL) fraction was significantly increased in
nephrotic patients (P < 0.05 vs. non-nephrotic controls; Table 2).
Conformably, the lyso-PC/PC ratio in the LDL-fraction divided by
the lyso-PC/PC ratio in total plasma was significantly increased in
nephrotic patients compared to non-nephrotic controls (P <
0.01), thus indicating a selective lyso-PC enrichment of the
LDL-fraction in nephrotic patients.
Nephrosis Glomerulonephritis Control
Creatinine .uno1/liter 83.1 8.7 81.2 5.4 82.8 3.1
Hemoglobin mmollliter 8.0 0.3 8.4 0.1 8.4 0.2
Hematocrit 0.37 0.02 0.39 0.01 0.39 0.01
Albumin glliter 22.8 14b1 37.8 1.2 37.1 0.6
Triglyceride mmol/liter
Cholesterol mmol/liter
3.6 1.1a
8.8 1.8'
1.4 0.3
4.4 0.3
1.1 0.2
3.9 0.3
LDL-cholesterol 4.61 0.40" 2.58 0.16 2.28 0.24
mmol/liter
Total phospholipids 3.42 011bd 2.32 0.06 2.18 0.08
inmol/liter
Lyso-PC in plasma 298.7 35.5 237.9 13.8 258.8 37.0
pnol/liter
Lyso-PC in LDL 65.6 10.laC 45.3 3.2 40.0 3.8
-fraction
.unol/liter
Lyso-PC/PC ratio in 0.78 0•05bd1 0.61 0.03 0.58 0.03
LDL divided by lyso-
PC/PC in total plasma
Baseline hemodynamic forearm measurements were not signif-
icantly different (Table 3), although there was a tendency towards
a decreased FBF in the nephrotic patients (Fig. 2). Within each
group there were no significant differences in baseline FBF's
before various infusion blocks (Table 3). There were also no
changes in FBF and FVR in the control arm during the cumula-
tive dose infusions (data not shown). Furthermore, there were no
significant changes in mean arterial pressure or heart rate during
the experiments. Thus, the changes in FBF and FVR in the
measurement arm may be interpreted as local vascular effects of
the infused drugs.
Effects of L-NMMA infusion
Inhibition of endogenous nitric oxide by L-NMMA (2 mg/mm)
decreased FBF by 30 4%, 39 4% and 37 2% in nephrotic
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Table 2. Biochemical parameters in plasma
Data are means SEM. Abbreviations are: Lyso-PC, lysophosphatidyl-
choline; PC, phosphatidylcholine; LDL, low-density lipoprotein.
ap < 0.5, °P < 0.01 vs. control
P < 0.05, dP < 0.01 vs. non-nephrotic glomerulonephritis
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Table 3. Forearm blood flows before and during drug infusions
Infused substance
Forearm blood flow mlii 00 ml forearm/mm
Saline + Coinfusion Dose I Dose II Dose III Dose IV
Nephrosis
Serotonin 2.3 0.4 — 2.8 0.4 3.3 0.5 3.9 0.5 —
Serotonin + L-arginine 2.4 0.4 2.5 0.4 2.9 0.3 3.7 0.5 4.6 0.5
Serotonin + L-NMMJ 2.4 0.3 1.7 0.3 — — 1.7 0.3
Nitroprusside 2.1 0.2 — 2.6 0.3 5.1 0.3" 10.2 0.7" 14.4 1.0"
Nitroprusside + L-arginine 2.3 0.3 2.4 0.3 3.5 0.5 5.5 0.6" 10.1 0.8" 15.2 1.3"
Glomerulonephritis
Serotonin 2.7 0.4 — 3.3 0.6 4.4 0.6 6.1 0.9"
Serotonin + L-arginine 2.6 0.4 2.6 0.4 3.4 0.4 4.3 0.5a 6.1 0.7"
Serotonin + L-NMMA 2.8 0.2 1.8 0.3a — 2.0 0.3 —
Nitroprusside
Nitroprusside + L-arginine
2.6 0.3
2.7 0.4
—
2.8 0.4
3.0 0.4
3.2 0.5
7.1 0.6"
8.6 0.8"
10.7 0.9"
12.1 0.7"
16.1 1.8"
17.1 1.7"
Control
Serotonin 2.7 0.3 — 3.9 0.4 4.7 0.5" 6.0 0.5"
Serotonin + L-arginine 2.6 0.3 2.6 0.3 3.4 0.4 4.7 0.6" 6.5 0.8"
Serotonin + L-NMMA 2.8 0.2 1.8 0.2 — 2.0 0.2 —
Nitroprusside
Nitroprusside + L-arginine
2.4 0.3
2.7 0.3
—
2.9 0.4
3.0 0.5
3.8 0.4
5.6 0.5"
6.8 0.5"
10.3 0.8"
11.5 1.3"
15.6 1.5"
16.7 1.9"
Forearm blood flows (means sEM) are given before drug infusion ('saline'), with only co-infused substance (+ co-infusion;
L-NMMA), and during the subsequent dosages of serotonin (Dose I, II and III) or nitroprusside (dose I, II, III and IV).
P < 0.5 compared to baseline
"P < 0.01 compared to baseline
L-arginine or
7
6
'4i
E
U-
LL
1
0
Fig. 2. Effect of nitric oxide inhibition by L-NMMA (A) and nitric oxide
stimulation by serotonin (B) on forearm blood flow. Basal forearm blood
flow is given in the middle panel. Symbols are: (U) nephrotic patients; ()
glomerulonephritic patients; (0) healthy controls. < 0.05 compared to
glomerulonephritic patients and healthy controls.
Effects of serotonin infusion
The highest dose of serotonin increased FBF from 2.3 0.4 to
3.9 0.5 ml/100 mi/mm in the nephrotic patients, from 2.7 0.4
to 6.1 0.9 mlIlOO mi/mm in the non-nephrotic group, and from
2.7 0.3 to 6.0 0.5 ml/100 mi/mm in the healthy controls (Table
3). Thus, as also illustrated in Figure 2, the serotonin-induced
vasodilation was clearly disturbed in the nephrotic patients (P <
0.05). Cumulative dose infusion of serotonin decreased FVR by
respectively 19 4%, 30 5%, and 40 5% in the nephrotic
patients, by 27 2%, 44 3%, and 56 3% in the patients with
non-proteinuric glomerulonephritis, and by 30 3%, 43 4%,
and 55 3% in the healthy controls (Fig. 3). The estimated
EC-25, expressed as [molar] log molar, was significantly lower for
the nephrotic patients (8.26 0.16) compared to the non-
nephrotic patients (8.76 0.08; P < 0.01), and the healthy
controls (8.81 0.11; P < 0.01). Increasing substrate availability
by administration of L-arginine did not signfficantly alter the
effects on FBF (Table 3) or the estimated EC-25 (8.36 0.15, 8.72
0.06, 8.74 0.09 for, respectively, nephrotic, non-nephrotic,
and healthy subjects). No significant correlations were found
within each group between serotonin-response and biochemical
parameters (hematocrit, plasma creatinine, albumin, or lyso-
PC/PC ratio). However, it must be realized that the range of
variation of the biochemical parameters within each group was
small, so that finding significant correlations may be unlikely.
Effects of nitroprusside infusion
patients, non-nephrotic patients and healthy controls (not signif-
icantly different; P = 0.15), respectively, causing almost identical
FBF's in the three study groups (Fig. 2 and Table 3). During
L-NMMA, the vasodilatory response to serotonin was abolished
in each group, confirming that serotonin-induced vasodilation is
mediated by the nitric oxide pathway (Table 3).
Administration of the endothelium-independent vasodilator
nitroprusside caused similar increments in FBF (Table 3). The
estimated EC-50 for decrease in FVR in the various groups also
did not differ (7.22 0.07 in nephrotic patients; 7.42 0.08 in
non-nephrotic glomerulonephritis and 7.30 0.11 in healthy
controls). The cumulative-dose infusion of nitroprusside resulted
in similar changes in FVR in the three groups (Fig. 3). Co-
infusion of L-arginine did not alter the effects on FBF (Table 3) or
*
L-NMMA Baseline Serotonin
A B
0
a)
25
50
C
0)0,
a)0) 75()
a)
I 100
8 7 8
the EC-50 values (7.23 0.09, 7.56 0.09 and 7.34 0.09, in,
respectively, nephrotic, non-nephrotic, and healthy controls; dif-
ferences not significant).
Discussion
The present study shows for the first time that patients
with nephrotic-range proteinuria have a defect in endothelium-
dependent vasodilation. In contrast, patients with non-nephrotic
glomerulonephritis have preserved endothelial function. Addition
of excess substrate for nitric oxide synthase, the amino acid
L-arginine, could not improve the defect in endothelial function.
To test whether basal nitric oxide activity was impaired in
nephrotic subjects, we administered the specific inhibitor of the
nitric oxide synthase, L-NMMA, in a dose very likely causing a
maximal response [17, 20]. A diminished constrictor response to
L-NMMA will then represent impaired basal release or effect of
nitric oxide. Although there was a tendency toward a decreased
response in the nephrotic subjects, this difference did not reach
significance. However, this does not exclude a defect in endothe-
ha! function. Basal nitric oxide release is determined by multiple
regulatory mechanisms, including mechanical forces and shear
stress, as well as receptor-dependent pathways (such as serotonin
released from aggregating platelets, bradykinin and thrombin)
[25, 26]. These multiple regulatory mechanisms may perhaps
compensate for, or mask, specific defects in nitric oxide activity.
Indeed, L-NMMA-induced vasoconstriction in subjects with hy-
percholesterolemia and atherosclerosis was not different from
that in normal subjects [27, 28], whereas acetyicholine-stimulated
nitric oxide activity is decreased in these patients [18, 19, 27—29].
We therefore also studied vasodilation during stimulation of
nitric oxide. For this purpose we measured serotonin-induced
vasodilation, which in the dosages used has been attributed
entirely to nitric oxide [15]. Indeed, L-NMMA administration
could completely block serotonin-induced vasodilation in the
present study. Patients with nephrotic range proteinuria displayed
a right and upward shift of the dose-response curve after intra-
arterial infusion of serotonin (Fig. 3) when compared to non-
nephrotic glomerulonephritis patients and healthy controls. In
contrast, the vasodilatory response to nitroprusside, indicating the
nitric oxide vasodilatory ability independent of endothelium, was
not different from that in the non-nephrotic patients or healthy
controls. These data, together with the finding that basal FBF
Fig. 3. Cumulative dose-response curves for
serotonin and nitroprusside in nephrotic patients
(V), non-nephrotic glomerulonephntic patients
(0) and controls (El). Curve-fitting analysis
demonstrated a significantly lower EC-25 for
...i serotonin in nephrotic patients, compared to
6 non-nephrotic controls (P < 0.01). Calculated
EC-50 values for nitroprusside were not
significantly different.
tended to be reduced as well, suggest that with progressive
stimulation of nitric oxide, endothelial function becomes more
impaired in patients with nephrotic-range proteinuria (Fig. 2).
Studies on hypercholesterolemia and re-endothelialization in
coronary arteries of pigs have postulated that the defect in
serotonin-stimulated vasodilation in atherosclerosis is dependent
upon a Gi-protein signal transduction system [30]. Such a system
may be coupled to a serotonergic, muscarinergic or alpha2-
adrenergic receptor [30]. Importantly, the Gi-protein-dependent
signal transduction system has also been implicated in maintaining
microvascular vasodilation during autoregulation and ischemia
[31]. The importance of these data obtained in experimental
animal studies, was recently confirmed in humans with hypercho-
lesterolemia, where serotonin-induced vasodilation (Gi-protein-
dependent) was decreased, while bradykinin-induced vasodilation
(Gi-protein-independent) was unimpaired [28]
Several factors may account for the decreased serotonin re-
sponse in nephrotic patients. In patients with glomerulonephritis
nitric oxide synthase activity may become limited by decreased
substrate availability due to accumulation of endogenous inhibi-
tors of nitric oxide synthase, such as asymmetrical dimethyl-
arginine [32], or increased arginase activity in the nephritic kidney
[33]. However, decreased substrate availability cannot explain the
defect in serotonin-induced vasodilation since GFR was normal in
these subjects and the defect was not present in the non-nephrotic
subjects with glomerulonephritis. Moreover, administration of
L-arginine could not improve serotonin-induced vasodilation,
although the amount administered in this study has been proven
sufficient to ameliorate impaired nitric oxide responses in hyper-
cholesterolemic patients [18, 19].
The proteinuric patients also had higher mean arterial pressure
levels than healthy controls, which may have contributed to the
impaired endothelial function. However, the data in the literature
are controversial. Studies in hypertensive patients have yielded
normal [34], as well as decreased [35] constrictor responses when
L-NMMA was infused in the brachial artery in similar dosages as
in the present study. Similarly, vasodilation upon infusion of
acetyicholine in the brachial artery was impaired in some studies
[36, 37]. However, a recently performed study in a large group of
hypertensive patients could not find a defect [38]. These different
results may be related to the severity and the duration of the
hypertension, resulting in a variable degree of endothelial damage
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[39]. In this respect it should be noted that our proteinuric
patients were young and hardly at all hypertensive, and that none
of the subjects had signs of macroangiopathy on physical exami-
nation. More important, the subjects with non-nephrotic glomer-
ulonephritis demonstrated similar arterial pressures (Table 1), but
had an unimpaired serotonin-induced nitric oxide response.
Another derangement that could have caused the decreased
nitric oxide-dependent vascular tone in the nephrotic patients is a
primary decrease in circulating fluid volume, since this would
cause a decrease in shear stress [40]. A decreased circulating
volume can indeed be expected in severe hypoproteinemia [41].
However, the somewhat higher arterial pressures in the nephrotic
group does not suggest a decrease in circulating volume. More-
over, in previous studies we found that nephrotic patients with
similar degrees of hypoproteinemia as found in the present
patients, have normal or somewhat elevated blood volumes [42,
43]. Reports on cardiac output in adults with the nephrotic
syndrome are scarce, but usually normal or slightly elevated values
have been shown [44, 45].
The results in proteinuric patients show striking similarity to
those obtained in hypercholesterolemic subjects [28]. Hypercho-
lesterolemia is also a hallmark of proteinuric renal disease,
notably resulting in very high levels of LDL. Experiments with
isolated vessels in organ chambers have shown that oxidized but
not native LDL could impair nitric oxide-mediated vasodilation
[46]. This effect on endothelial-dependent vasodilation could be
attributed entirely to the lysophosphatidylcholine (lyso-PC) accu-
mulation that occurs during oxidative modification of LDL [47], and
was caused by interference with the Gi-protein-dependent signal
transduction system [48]. Our patients with proteinuria had markedly
elevated levels of LDL cholesterol. In addition, the lyso-PC content
of the LDL lipoproteins, as indicated by the lyso-PC7PC ratio, was
also increased (Table 2). These high levels of lyso-PC enriched LDL
particles would suggest enhanced intravascular modification of LDL
in proteinuric patients. Alternatively, in the presence of hypoalbu-
minemia, lyso-PC formed by the LCAT reaction may also bind to
lipoproteins, and not exclusively to albumin [22]. Although the
present data fit well with the postulated mechanisms by which
hypercholesterolemia may cause endothelial dysfunction, this rela-
tionship can only be firmly established by studying the effect of
interventions on lipid metabolism in these patients.
The clinical relevance of our data pertains to the role of nitric
oxide as a protective mechanism against vascular injury. Nitric
oxide not only maintains vasodilatory tone [8, 9], it also prevents
platelet adhesion and aggregate formation [11], inhibits vascular
smooth muscle proliferation [10] and leukocyte adhesion [49], and
probably antagonizes lipoprotein flux towards the subendothe-
hum [12]. Indeed, long-term inhibition of nitric oxide formation is
associated with accelerated atherosclerosis in animals [50].As we
have shown previously, nephrotic patients have an increased
coagulatory response to vascular injury, even in the absence of overt
macrovascular disease [51]. Therefore, the presently observed im-
paired vasodilatory response to serotonin, and thus decreased release
and/or activity of nitric oxide, may imply a defective endothelial
defense mechanism against vascular injury, and thus a major cardio-
vascular risk It should be realized that the present observations were
made in relatively young patients. Our data therefore lend further
support for early active treatment of cardiovascular risk factors in
patients with nephrotic range proteinuria.
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